New H1N1 strain can be treated with mainstay drugs, says
MOH, A*Star
SINGAPORE: The Health Ministry and government
research agency A*Star said the new H1N1 strain can still be
treated with mainstay drugs.
The new strain has a rare-occurring mutation that
causes it to be mildly resistant to Tamiflu. And when mixed with a
more common Tamiflu-resistant mutation, the variant leads to a much
stronger reduction in drug sensitivity.
But the MOH and A*Star has said the new strain can
still be effectively treated with drugs like Tamiflu and Relenza.
They said most people with the flu will make a full recovery
without the need for antiviral drugs.
And the Ministry has advised those who are at a higher risk of
complications, to get vaccinated against the flu annually. They
include the elderly, young children and those with chronic heart
and respiratory diseases.
The authorities said Singapore is at the cross-roads between the
northern and southern hemispheres, and as a result, has year-round
circulations of influenza viruses. As such they would continue to
monitor the virus for further changes.
The new variant was discovered in Singapore and Australia by the
World Health Organisation's Influenza Collaborating Centre and
Singapore's National Public Health Laboratory (NPHL) and A*STAR's
Bioinformatics Institute (BII).
-CNA/ac